Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sodium valproate in preparation of medicament for treating or improving optic nerve pathological changes of glaucoma

A technology of optic neuropathy and sodium valproate, applied in the direction of drug combination, active ingredients of anhydride/acid/halide, sensory diseases, etc., can solve the problems of limited clinical curative effect, achieve good effect, not easy to degrade, and good social and economic benefits Effect

Inactive Publication Date: 2011-10-19
EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current clinical treatment methods, including lowering intraocular pressure or neuroprotective agents, often only try to delay the death of RGCs by targeting one of the above-mentioned many pathogenic factors, and rarely can cause the death of RGCs by two or more at the same time. The drug or method used as the target of treatment, so the clinical efficacy is limited
So far, there are no reports that sodium valproate can interfere with multiple pathogenesis of glaucomatous RGCs death through multiple therapeutic targets, improve the effect of protecting retinal ganglion cells and their axons, especially improve or treat glaucomatous optic neuropathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium valproate in preparation of medicament for treating or improving optic nerve pathological changes of glaucoma
  • Application of sodium valproate in preparation of medicament for treating or improving optic nerve pathological changes of glaucoma
  • Application of sodium valproate in preparation of medicament for treating or improving optic nerve pathological changes of glaucoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 VPA promotes the survival and axonal growth of adult SD rat retinal ganglion cells cultured in vitro

[0022] 1. Materials and methods

[0023] 1. Drug: sodium valproate (VPA), product of sigma company.

[0024] 2. Animals: Healthy SD rats (provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences), male, 8 weeks old, and weighing 180-200 g were selected as experimental animals, and were bred in the animal center of the hospital.

[0025]3. Main materials and reagents: fetal bovine serum (product of Gibco), bovine serum albumin (BSA, product of Sigma), Neurobasal medium and B27 (product of Gibco), papain and ovomucin (product of Sigma) , recombinant neurotrophic factors BDNF and CNNF (products of Invitrogen), basic fibroblast growth factor bFGF (products of Invitrogen), glutamine (products of Sigma), OX-42 monoclonal antibody, survivin monoclonal antibody, Bcl- 2 The monoclonal antibody was purchased from Chemicon, the GFAP polyc...

Embodiment 2

[0036] Example 2 Effect of VPA on Retinal Ganglion Cells of SD Rats with Chronic Hypertension

[0037] 1. Materials and methods

[0038] 1. Drug: sodium valproate (VPA), product of sigma company.

[0039] 2. Animals: The experimental animals were healthy SD rats (provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences), male, 8 weeks old, weighing 180-200 g, and raised in the animal center of the hospital (12 hours of light and 12 hours of darkness).

[0040] 3. Main materials and reagents

[0041] Fluorescent gold: product of Invitrogen Company.

[0042] OX-42 monoclonal antibody and survivin monoclonal antibody were purchased from Chemicon; Bcl-2 monoclonal antibody and GFAP polyclonal antibody were purchased from Neomarker; α-synuclein and catenin monoclonal antibodies were purchased from R&D Company.

[0043] TNF-αimmunoenzyme-linked reaction kit (Elisa) is a product of Invitrogen.

[0044] 2. Experimental method

[0045] 1. Establishmen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy, and relates to application of sodium valproate in preparation of medicaments for treating or improving optic nerve pathological changes of glaucoma. The in-vitro cell culture experiment and in-vivo animal experiment indicate that sodium valproate with certain concentration can promote retina ganglionic cells (RGCs) cultured in vitro to survive and enhance the extension capacity of the axon, and can lower the expression of proapoptotic gene BAX and promote the RGCs to survive under the conditions of chronic high intraocular pressure, thereby relieving the damage of RGCs. The experiments prove that the sodium valproate can protect the RGCs in the aspects of multiple pathogeneses of glaucoma optic nerve pathological changes, and further more, can be used as an active ingredient for preaprating medicaments for treating glaucoma optic nerve pathological changes, especially medicaments for protecting RGCs. The invention has important application value and favorable social and economic benefits in clinical treatment of glaucoma.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a new application of sodium valproate in pharmacy, in particular to the application of sodium valproate in the preparation of medicines for treating or improving glaucomatous optic neuropathy. Background technique [0002] Glaucoma is a type of optic neuropathy characterized by retinal ganglion cell (RGC) apoptosis and progressive axonal degeneration. It is the second most common blindness in the world after cataract. In 2000, there were about 66.8 million primary glaucoma patients and about 6 million secondary glaucoma patients in the world, of which about 6.7 million patients were blinded by glaucoma; it is estimated that by 2020, more than 3 million people in the United States will suffer from glaucoma, at least 8 Thousands of people will eventually lose their sight. In China, 5.2 million of the 9.4 million glaucoma patients are blind, and the blinding rate is almost close to that of ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/19A61P27/06A61P39/02A61P27/02
Inventor 孙兴怀张圣海吴继红武娜杨伯齐王楷迪
Owner EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com